The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
it is never a good idea to top up on a bad day, because you do not know what is going to happen tomorrow, see NCYT.
I normally wish every investor well, and I feel sorry for the ones who tried run after the money selling Avacta and buying NCYT yesterday. But today I feel a bit of SCHADENFREUDE.
no, and it will take up to 4 years to vaccinate the whole population.
the instrument they use to analyse the test looks massive - no comparison.
amateur investor - I really cannot follow your arguments. NCYT is a success story, so is Tesla, but nobody can predict this beforehand. Right now I am very happy with the SP of Avacta, the way is has developed over the last few weeks, and the way it reacted to the news yesterday, and the bounce back after AI's presentation. I am here because, based on my research, I conclude that Avacta might be as successful as TESLA (I leave NCYT out, because I cannot see the long term vision). The news yesterday, and more negative news that might come, will only be small setbacks on a great success story.
merchantvanker - I feel sorry for everyone who sold on this news, buying back is more expensive now.
I fully agree with again wyndrum. he would not be allowed to sell right after an RNS.
some people seem to know more than us again
so what?
Gazza - you must have read nothing, that is not a good investment strategy.
short answer, no. I read in the FAZ (major german newspaper), that even if they will receive a vaccine mid this year, it will take about 4 years to get the whole population vaccinated. The UK will not be quicker.
you can't even calculate your profit correctly.
another post by an amateur investor
went in much higher, and feel very confident. selling now makes absolutely no sense to me. thank you for your advise though - ignored.
I agree with CO, but given the low trading volume, and the fact that buyers are willing to pay a higher share price, I agree more with wyndrum's suggesting - something is going on behind the scenes. let's wait and see ...
I guess that is it just a question of demand and availability, and the trading volume itself does not matter that much. why there seems to be more demand today, we can only guess.
wyndrum - thanks for correcting me. Perhaps you can also help me understand how a relatively low trading volume today so far (600k, read from investing UK), which is only a fraction of a percent of the shares outstanding, can change Avacta's share price by 7 percent?
it simply was oversold
there is no further information to this news, so I do not understand why it is worth a news report. As with all other tests that will come on the market, they will have the drawbacks related to using antibodies.
This is a climbs of what Avacta's test might look like. Can't wait!
https://www.siemens-healthineers.com/press-room/press-releases/covid-19-poc-rapid-antigentest.html